Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma

(2011) D. R. Johnson et al.   NEURO-ONCOLOGY

Bevacizumab-induced regression of anaplastic meningioma

(2010) M. J. A. Puchner et al.   ANNALS OF ONCOLOGY

Management of meningiomas

(2010) George A. Alexiou et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Intracranial meningiomas of atypical (WHO grade II) histology

(2010) Leland Rogers et al.   JOURNAL OF NEURO-ONCOLOGY

A review of malignant meningiomas: diagnosis, characteristics, and treatment

(2010) Simon Hanft et al.   JOURNAL OF NEURO-ONCOLOGY

Aberrant signaling pathways in meningiomas

(2010) Brian T. Ragel et al.   JOURNAL OF NEURO-ONCOLOGY

Pathological classification and molecular genetics of meningiomas

(2010) Christian Mawrin et al.   JOURNAL OF NEURO-ONCOLOGY

Medical therapies for meningiomas

(2010) Patrick Y. Wen et al.   JOURNAL OF NEURO-ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of neo-angiogenesis in a case of chordoid meningioma

(2009) Valeria Barresi et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma

(2009) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)

(2009) Patrick Y. Wen et al.   NEURO-ONCOLOGY

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Interferon-α for recurrent World Health Organization grade 1 intracranial meningiomas

(2008) Marc C. Chamberlain et al.   CANCER

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY